Literature DB >> 23690114

Interobserver variability and feasibility of polymerase chain reaction-based assay in distinguishing ischemic colitis from Clostridium difficile colitis in endoscopic mucosal biopsies.

Homer O Wiland1, Gary W Procop, John R Goldblum, Marion Tuohy, Lisa Rybicki, Deepa T Patil.   

Abstract

Polymerase chain reaction (PCR)-based assays using stool samples are currently the most effective method of detecting Clostridium difficile. This study examines the feasibility of this assay using mucosal biopsy samples and evaluates the interobserver reproducibility in diagnosing and distinguishing ischemic colitis from C difficile colitis. Thirty-eight biopsy specimens were reviewed and classified by 3 observers into C difficile and ischemic colitis. The findings were correlated with clinical data. PCR was performed on 34 cases using BD GeneOhm C difficile assay. The histologic interobserver agreement was excellent (κ= 0.86) and the agreement between histologic and clinical diagnosis was good (κ = 0.84). All 19 ischemic colitis cases tested negative (100% specificity) and 3 of 15 cases of C difficile colitis tested positive (20% sensitivity). C difficile colitis can be reliably distinguished from ischemic colitis using histologic criteria. The C difficile PCR test on endoscopic biopsy specimens has excellent specificity but limited sensitivity.

Entities:  

Keywords:  Clostridium difficile; Endoscopic mucosal biopsies; Ischemic colitis; Polymerase chain reaction

Mesh:

Substances:

Year:  2013        PMID: 23690114     DOI: 10.1309/AJCPG8AYN9MUWJXV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  1 in total

1.  Analysis of TaqMan Array Cards Data by an Assumption-Free Improvement of the maxRatio Algorithm Is More Accurate than the Cycle-Threshold Method.

Authors:  Luigi Marongiu; Eric Shain; Lydia Drumright; Reidun Lillestøl; Donald Somasunderam; Martin D Curran
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.